HRMY Harmony Biosciences Holdings

Paradiem LLC recently acquired 26,279 shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) for approximately $724,000, contributing to the company's high institutional ownership of 86.23%. While Harmony Biosciences missed Q3 EPS estimates, its revenue surpassed expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $45.63. Insiders also own 23.6% of the stock, with recent insider selling activity noted.

Exchange Traded Concepts LLC significantly increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 102.6% in the third quarter, acquiring an additional 32,923 shares. This brings their total holdings to 65,023 shares, valued at approximately $1.79 million. The article also notes that CEO Jeffrey M. Dayno sold a substantial number of shares, and analysts maintain a "Moderate Buy" consensus rating with a target price of $45.63 for HRMY.

Harmony Biosciences (NASDAQ:HRMY) saw its stock price drop by 3.9% after CEO Jeffrey M. Dayno sold 25,933 shares for over $1 million. The stock traded at $37.2550, with trading volume significantly below average. Despite the drop, analysts maintain a "Moderate Buy" consensus rating with a target price of $45.63, though individual targets vary.

Jeffrey M. Dayno, President and CEO of Harmony Biosciences Holdings and a 10% owner, sold 25,933 shares of common stock for $1,040,102 on December 12, 2025. This transaction, executed under a Rule 10b5-1 trading plan, leaves Dayno with no direct ownership in the company's common stock. The sale price was a weighted average of $40.1073 per share.

Harmony Biosciences Holdings, Inc. CEO and Director, Jeffrey M. Dayno, executed a stock option for 20,000 shares at $8.22 per share on December 12, 2025. On the same day, he sold a total of 25,933 shares in open-market transactions, priced between $40.00 and $40.28, under a Rule 10b5-1 trading plan. Following these transactions, the CEO beneficially owns 0 shares of common stock directly from this option grant.

Harmony Biosciences CEO Jeffrey Dayno sold 25,933 shares of the company's stock on December 12th for over $1 million. The stock traded down $0.05 to $38.78 on Wednesday, while market capitalization stands at $2.23 billion with a P/E ratio of 12.20. Despite missing Q3 EPS estimates, the company's revenue beat expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $45.63.